Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
AssigneeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsGyorgy Petrovics, Shiv Srivastava
Life of this patent
Estimating the term…
Abstract
The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
Claims8
An isolated monoclonal antibody that binds to ERG, wherein the antibody binds to an epitope located within amino acids 278-363 of the polypeptide encoded by a nucleic acid comprising the sequence of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.